MIT News
June 2, 2020
A team led by White Lab grad student Lauren Stopfer developed a tool that may help researchers and clinicians make cancer immunotherapies more effective: a platform that precisely quantifies the number of antigens presented on cell surfaces. In a study appearing in Nature Communications, researchers profiled changes in cell-surface antigens resulting from treatment with CDK4/6 inhibitors, a class of anticancer agents. Their results added to a growing body of evidence that CDK4/6 inhibitors may increase the effectiveness of immune checkpoint blockade inhibitors, and demonstrated that the platform could be used to identify new immunotherapy targets. Because of its sensitivity and speed, the new platform could be used in the clinic to tailor treatment strategies to individual patients.
This study was funded in part by the MIT Center for Precision Cancer Medicine and the Koch Institute Frontier Research Program through the Kathy and Curt Marble Cancer Research Fund.